442 related articles for article (PubMed ID: 30317578)
1. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
[TBL] [Abstract][Full Text] [Related]
2. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
3. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
4. Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Fei YQ; Shi RT; Zhou YF; Wu JZ; Song Z
Neurochem Int; 2022 Jul; 157():105348. PubMed ID: 35490896
[TBL] [Abstract][Full Text] [Related]
5. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
8. A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Liu T; Hu J; Han B; Tan S; Jia W; Xin Y
Cell Death Dis; 2021 Oct; 12(11):952. PubMed ID: 34657141
[TBL] [Abstract][Full Text] [Related]
9. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
10. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
11. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
[TBL] [Abstract][Full Text] [Related]
13. Circ
Li J; Ma J; Huang S; Li J; Zhou L; Sun J; Chen L
Mol Cell Biol; 2023; 43(7):354-369. PubMed ID: 37427890
[TBL] [Abstract][Full Text] [Related]
14. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
He X; Sheng J; Yu W; Wang K; Zhu S; Liu Q
Cell Mol Neurobiol; 2021 Aug; 41(6):1271-1284. PubMed ID: 32529543
[TBL] [Abstract][Full Text] [Related]
16. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
18. RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Sun J; Ma Q; Li B; Wang C; Mo L; Zhang X; Tang F; Wang Q; Yan X; Yao X; Wu Q; Shu C; Xiong J; Fan W; Wang J
Cell Death Dis; 2020 Oct; 11(10):890. PubMed ID: 33087705
[TBL] [Abstract][Full Text] [Related]
19. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
20. Modulating Wnt/β-Catenin Signaling Pathway on U251 and T98G Glioblastoma Cell Lines Using a Combination of Paclitaxel and Temozolomide, A Molecular Docking Simulations and Gene Expression Study.
Jamalpour S; Alinezhad A; Sabah JT; Vazifehmand R; Behrooz AB; Hamzah ASA; Davazdahemami AA; Homaie FM; Maddah SM
Chem Pharm Bull (Tokyo); 2023; 71(10):766-774. PubMed ID: 37779078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
